ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ THẢI SẮT TRÊN BỆNH NHÂN THALASSEMIA CÓ QUÁ TẢI SẮT BẰNG DEFERASIROX TẠI BỆNH VIỆN TRUNG ƯƠNG THÁI NGUYÊN

Abstract

Objective: To evaluate the results of Deferasirox treatment in pediatric patients Beta Thalassemia with heart failure due to iron overload. Subjects: 32 Beta thalassemia patients diagnosed with heart failure due to iron overload at the Department of Clinical Hematology in Thai Nguyen National Hospital from 01/2021 to 6/2021. Methods: A descriptive Cross-sectional. Results: 32 patients followed up treatment results during the study period: The rates of patients with severe iron overload before and after treatment were 75.00% and 68.76%, respectively. The difference was not statistically significant with p> 0.05. The proportion of patients with severe iron overload after treatment with a reduction in the force of myocardial contractility was 54.17%, lower than the rate before treatment of 62.50%. The proportion of patients with severe iron overload after treatment with heart arrhythmia was (58.33%), lower than the rate before treatment (70.83%). Conclusion: The rate of male patients is 53.12%, female is 46.88%. The average hemoglobin in the male and female patients groups were: 71.9 ± 15.4 and 77.5 ±16.1, respectively. Deferasirox 35-50mg/kg/24h combined with blood transfusion ensures Hb > 100 g/l no increase in iron overload and heart failure complications in patients beta thalassemia